Fresenius Medical Care Of Marlborough is a medicare approved dialysis facility center in Marlborough, Massachusetts and it has 13 dialysis stations. It is located in Middlesex county at 360 Cedar Hill Street, Marlborough, MA, 01752. You can reach out to the office of Fresenius Medical Care Of Marlborough at (508) 460-9250. This dialysis clinic is managed and/or owned by Fresenius Medical Care. Fresenius Medical Care Of Marlborough has the following ownership type - Profit. It was first certified by medicare in October, 2007. The medicare id for this facility is 222570 and it accepts patients under medicare ESRD program.
Name | Fresenius Medical Care Of Marlborough |
---|---|
Location | 360 Cedar Hill Street, Marlborough, Massachusetts |
No. of Dialysis Stations | 13 |
Medicare ID | 222570 |
Managed By | Fresenius Medical Care |
Ownership Type | Profit |
Late Shifts | No |
360 Cedar Hill Street, Marlborough, Massachusetts, 01752 | |
(508) 460-9250 | |
News Archive
Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that it has raised $33.9 million in a Series B funding round, led by new investor, New Enterprise Associates ("NEA"), one of the world's leading venture capital firms. Existing investor, Sofinnova Partners, also participated in the financing.
Mylan Inc. today announced the U.S. launch of its Methocarbamol Injection USP, 100 mg/mL, packaged in 1,000 mg/10 mL single-dose vials. This product is the generic version of Hikma Maple Ltd.'s Robaxin.
Eclipsys Corporation®, The Outcomes Company®, today announced that Singapore General Hospital, Singapore's oldest and largest acute tertiary hospital and national referral center, has been recognized as a winner of the Microsoft HUG 2010 Innovation Awards in the category of "Best Use of Clinical Records — Inpatient."
Good timing is vital in many situations of daily life, but is rarely something we consider. In a new dissertation from Umeå University in Sweden, Olympia Karampela shows that our ability for timing is something that can be trained and it seems to be connected with our cognitive capacity.
› Verified 3 days ago
NPI Number | 1164840484 |
Organization Name | Fresenius Medical Care Marlborough |
Doing Business As | Fresenius Medical Care Cnv Marlborough, Llc |
Address | 360 Cedar Hill St Marlborough, Massachusetts, 01752 |
Phone Number | (508) 460-9250 |
News Archive
Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that it has raised $33.9 million in a Series B funding round, led by new investor, New Enterprise Associates ("NEA"), one of the world's leading venture capital firms. Existing investor, Sofinnova Partners, also participated in the financing.
Mylan Inc. today announced the U.S. launch of its Methocarbamol Injection USP, 100 mg/mL, packaged in 1,000 mg/10 mL single-dose vials. This product is the generic version of Hikma Maple Ltd.'s Robaxin.
Eclipsys Corporation®, The Outcomes Company®, today announced that Singapore General Hospital, Singapore's oldest and largest acute tertiary hospital and national referral center, has been recognized as a winner of the Microsoft HUG 2010 Innovation Awards in the category of "Best Use of Clinical Records — Inpatient."
Good timing is vital in many situations of daily life, but is rarely something we consider. In a new dissertation from Umeå University in Sweden, Olympia Karampela shows that our ability for timing is something that can be trained and it seems to be connected with our cognitive capacity.
› Verified 3 days ago
NPI Number | 1255389078 |
Organization Name | Fresenius Medical Care Of Marlborough |
Doing Business As | Bio-medical Applications Of Massachusetts, Inc. |
Address | 360 Cedar Hill St Marlborough, Massachusetts, 01752 |
Phone Number | (508) 460-9250 |
News Archive
Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that it has raised $33.9 million in a Series B funding round, led by new investor, New Enterprise Associates ("NEA"), one of the world's leading venture capital firms. Existing investor, Sofinnova Partners, also participated in the financing.
Mylan Inc. today announced the U.S. launch of its Methocarbamol Injection USP, 100 mg/mL, packaged in 1,000 mg/10 mL single-dose vials. This product is the generic version of Hikma Maple Ltd.'s Robaxin.
Eclipsys Corporation®, The Outcomes Company®, today announced that Singapore General Hospital, Singapore's oldest and largest acute tertiary hospital and national referral center, has been recognized as a winner of the Microsoft HUG 2010 Innovation Awards in the category of "Best Use of Clinical Records — Inpatient."
Good timing is vital in many situations of daily life, but is rarely something we consider. In a new dissertation from Umeå University in Sweden, Olympia Karampela shows that our ability for timing is something that can be trained and it seems to be connected with our cognitive capacity.
› Verified 3 days ago
Experience Measure | Provider | National Avg. |
---|---|---|
Patients who reported that nephrologists always communicated and cared for them. | 70% | 67% |
Patients who reported that nephrologists usually communicated and cared for them. | 11% | 15% |
Patients who reported that nephrologists sometimes or never communicated and cared for them. | 19% | 18% |
Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 63% | 60% |
Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 28% | 26% |
Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 9% | 14% |
News Archive
Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that it has raised $33.9 million in a Series B funding round, led by new investor, New Enterprise Associates ("NEA"), one of the world's leading venture capital firms. Existing investor, Sofinnova Partners, also participated in the financing.
Mylan Inc. today announced the U.S. launch of its Methocarbamol Injection USP, 100 mg/mL, packaged in 1,000 mg/10 mL single-dose vials. This product is the generic version of Hikma Maple Ltd.'s Robaxin.
Eclipsys Corporation®, The Outcomes Company®, today announced that Singapore General Hospital, Singapore's oldest and largest acute tertiary hospital and national referral center, has been recognized as a winner of the Microsoft HUG 2010 Innovation Awards in the category of "Best Use of Clinical Records — Inpatient."
Good timing is vital in many situations of daily life, but is rarely something we consider. In a new dissertation from Umeå University in Sweden, Olympia Karampela shows that our ability for timing is something that can be trained and it seems to be connected with our cognitive capacity.
› Verified 3 days ago
Experience Measure | Provider | National Avg. |
---|---|---|
Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 69% | 62% |
Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 9% | 20% |
Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 22% | 18% |
Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 71% | 62% |
Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 21% | 26% |
Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 8% | 12% |
News Archive
Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that it has raised $33.9 million in a Series B funding round, led by new investor, New Enterprise Associates ("NEA"), one of the world's leading venture capital firms. Existing investor, Sofinnova Partners, also participated in the financing.
Mylan Inc. today announced the U.S. launch of its Methocarbamol Injection USP, 100 mg/mL, packaged in 1,000 mg/10 mL single-dose vials. This product is the generic version of Hikma Maple Ltd.'s Robaxin.
Eclipsys Corporation®, The Outcomes Company®, today announced that Singapore General Hospital, Singapore's oldest and largest acute tertiary hospital and national referral center, has been recognized as a winner of the Microsoft HUG 2010 Innovation Awards in the category of "Best Use of Clinical Records — Inpatient."
Good timing is vital in many situations of daily life, but is rarely something we consider. In a new dissertation from Umeå University in Sweden, Olympia Karampela shows that our ability for timing is something that can be trained and it seems to be connected with our cognitive capacity.
› Verified 3 days ago
Experience Measure | Provider | National Avg. |
---|---|---|
Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 81% | 80% |
Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 19% | 20% |
Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 80% | 68% |
Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 13% | 20% |
Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 7% | 12% |
News Archive
Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that it has raised $33.9 million in a Series B funding round, led by new investor, New Enterprise Associates ("NEA"), one of the world's leading venture capital firms. Existing investor, Sofinnova Partners, also participated in the financing.
Mylan Inc. today announced the U.S. launch of its Methocarbamol Injection USP, 100 mg/mL, packaged in 1,000 mg/10 mL single-dose vials. This product is the generic version of Hikma Maple Ltd.'s Robaxin.
Eclipsys Corporation®, The Outcomes Company®, today announced that Singapore General Hospital, Singapore's oldest and largest acute tertiary hospital and national referral center, has been recognized as a winner of the Microsoft HUG 2010 Innovation Awards in the category of "Best Use of Clinical Records — Inpatient."
Good timing is vital in many situations of daily life, but is rarely something we consider. In a new dissertation from Umeå University in Sweden, Olympia Karampela shows that our ability for timing is something that can be trained and it seems to be connected with our cognitive capacity.
› Verified 3 days ago
Dialysis patients with Hemoglobin data | 45 |
Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 16 |
News Archive
Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that it has raised $33.9 million in a Series B funding round, led by new investor, New Enterprise Associates ("NEA"), one of the world's leading venture capital firms. Existing investor, Sofinnova Partners, also participated in the financing.
Mylan Inc. today announced the U.S. launch of its Methocarbamol Injection USP, 100 mg/mL, packaged in 1,000 mg/10 mL single-dose vials. This product is the generic version of Hikma Maple Ltd.'s Robaxin.
Eclipsys Corporation®, The Outcomes Company®, today announced that Singapore General Hospital, Singapore's oldest and largest acute tertiary hospital and national referral center, has been recognized as a winner of the Microsoft HUG 2010 Innovation Awards in the category of "Best Use of Clinical Records — Inpatient."
Good timing is vital in many situations of daily life, but is rarely something we consider. In a new dissertation from Umeå University in Sweden, Olympia Karampela shows that our ability for timing is something that can be trained and it seems to be connected with our cognitive capacity.
› Verified 3 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
Adult patients getting regular hemodialysis at the center | 70 |
Adult patient months included in Kt/V greater than or equal to 1.2 | 607 |
Percentage of adult patients getting regular hemodialysis at the center | 97 |
Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that it has raised $33.9 million in a Series B funding round, led by new investor, New Enterprise Associates ("NEA"), one of the world's leading venture capital firms. Existing investor, Sofinnova Partners, also participated in the financing.
Mylan Inc. today announced the U.S. launch of its Methocarbamol Injection USP, 100 mg/mL, packaged in 1,000 mg/10 mL single-dose vials. This product is the generic version of Hikma Maple Ltd.'s Robaxin.
Eclipsys Corporation®, The Outcomes Company®, today announced that Singapore General Hospital, Singapore's oldest and largest acute tertiary hospital and national referral center, has been recognized as a winner of the Microsoft HUG 2010 Innovation Awards in the category of "Best Use of Clinical Records — Inpatient."
Good timing is vital in many situations of daily life, but is rarely something we consider. In a new dissertation from Umeå University in Sweden, Olympia Karampela shows that our ability for timing is something that can be trained and it seems to be connected with our cognitive capacity.
› Verified 3 days ago
Adult patients getting regular peritoneal dialysis at the center | 10 |
Adult patient months included in Kt/V greater than or equal to 1.7 | 76 |
Percentage of adult patients getting regular peritoneal dialysis at the center | |
Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that it has raised $33.9 million in a Series B funding round, led by new investor, New Enterprise Associates ("NEA"), one of the world's leading venture capital firms. Existing investor, Sofinnova Partners, also participated in the financing.
Mylan Inc. today announced the U.S. launch of its Methocarbamol Injection USP, 100 mg/mL, packaged in 1,000 mg/10 mL single-dose vials. This product is the generic version of Hikma Maple Ltd.'s Robaxin.
Eclipsys Corporation®, The Outcomes Company®, today announced that Singapore General Hospital, Singapore's oldest and largest acute tertiary hospital and national referral center, has been recognized as a winner of the Microsoft HUG 2010 Innovation Awards in the category of "Best Use of Clinical Records — Inpatient."
Good timing is vital in many situations of daily life, but is rarely something we consider. In a new dissertation from Umeå University in Sweden, Olympia Karampela shows that our ability for timing is something that can be trained and it seems to be connected with our cognitive capacity.
› Verified 3 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Fresenius Medical Care Of Marlborough with elevated calcium levels.
Patients with hypercalcemia | 85 |
Hypercalcemia patient months | 732 |
Hypercalcemia patients with serumcalcium greater than 10.2 mg | 1 |
Patients with Serumphosphor | 94 |
Patients with Serumphosphor less than 3.5 mg/dL | 11 |
Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 30 |
Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 28 |
Patients with Serumphosphor from 5.6 to 7 mg/dL | 18 |
Patients with Serumphosphor greater than 7 mg/dL | 14 |
News Archive
Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that it has raised $33.9 million in a Series B funding round, led by new investor, New Enterprise Associates ("NEA"), one of the world's leading venture capital firms. Existing investor, Sofinnova Partners, also participated in the financing.
Mylan Inc. today announced the U.S. launch of its Methocarbamol Injection USP, 100 mg/mL, packaged in 1,000 mg/10 mL single-dose vials. This product is the generic version of Hikma Maple Ltd.'s Robaxin.
Eclipsys Corporation®, The Outcomes Company®, today announced that Singapore General Hospital, Singapore's oldest and largest acute tertiary hospital and national referral center, has been recognized as a winner of the Microsoft HUG 2010 Innovation Awards in the category of "Best Use of Clinical Records — Inpatient."
Good timing is vital in many situations of daily life, but is rarely something we consider. In a new dissertation from Umeå University in Sweden, Olympia Karampela shows that our ability for timing is something that can be trained and it seems to be connected with our cognitive capacity.
› Verified 3 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
Patients included in arterial venous fistula and catheter summaries | 67 |
Patient months included in arterial venous fistula and catheter summaries | 519 |
Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 84 |
Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 6 |
News Archive
Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that it has raised $33.9 million in a Series B funding round, led by new investor, New Enterprise Associates ("NEA"), one of the world's leading venture capital firms. Existing investor, Sofinnova Partners, also participated in the financing.
Mylan Inc. today announced the U.S. launch of its Methocarbamol Injection USP, 100 mg/mL, packaged in 1,000 mg/10 mL single-dose vials. This product is the generic version of Hikma Maple Ltd.'s Robaxin.
Eclipsys Corporation®, The Outcomes Company®, today announced that Singapore General Hospital, Singapore's oldest and largest acute tertiary hospital and national referral center, has been recognized as a winner of the Microsoft HUG 2010 Innovation Awards in the category of "Best Use of Clinical Records — Inpatient."
Good timing is vital in many situations of daily life, but is rarely something we consider. In a new dissertation from Umeå University in Sweden, Olympia Karampela shows that our ability for timing is something that can be trained and it seems to be connected with our cognitive capacity.
› Verified 3 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
Patients in facility's Hospitalization Summary | 61 |
Hospitalization Rate in facility | 143.6 (As Expected) |
Hospitalization Rate: Upper Confidence Limit | 253.3 |
Hospitalization Rate: Lower Confidence Limit | 84.7 |
News Archive
Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that it has raised $33.9 million in a Series B funding round, led by new investor, New Enterprise Associates ("NEA"), one of the world's leading venture capital firms. Existing investor, Sofinnova Partners, also participated in the financing.
Mylan Inc. today announced the U.S. launch of its Methocarbamol Injection USP, 100 mg/mL, packaged in 1,000 mg/10 mL single-dose vials. This product is the generic version of Hikma Maple Ltd.'s Robaxin.
Eclipsys Corporation®, The Outcomes Company®, today announced that Singapore General Hospital, Singapore's oldest and largest acute tertiary hospital and national referral center, has been recognized as a winner of the Microsoft HUG 2010 Innovation Awards in the category of "Best Use of Clinical Records — Inpatient."
Good timing is vital in many situations of daily life, but is rarely something we consider. In a new dissertation from Umeå University in Sweden, Olympia Karampela shows that our ability for timing is something that can be trained and it seems to be connected with our cognitive capacity.
› Verified 3 days ago
The rate of readmission show you whether patients who were being treated regularly at Fresenius Medical Care Of Marlborough were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
Readmission Rate in facility | 30.9 (As Expected) |
Readmission Rate: Upper Confidence Limit | 43.6 |
Readmission Rate: Lower Confidence Limit | 20 |
News Archive
Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that it has raised $33.9 million in a Series B funding round, led by new investor, New Enterprise Associates ("NEA"), one of the world's leading venture capital firms. Existing investor, Sofinnova Partners, also participated in the financing.
Mylan Inc. today announced the U.S. launch of its Methocarbamol Injection USP, 100 mg/mL, packaged in 1,000 mg/10 mL single-dose vials. This product is the generic version of Hikma Maple Ltd.'s Robaxin.
Eclipsys Corporation®, The Outcomes Company®, today announced that Singapore General Hospital, Singapore's oldest and largest acute tertiary hospital and national referral center, has been recognized as a winner of the Microsoft HUG 2010 Innovation Awards in the category of "Best Use of Clinical Records — Inpatient."
Good timing is vital in many situations of daily life, but is rarely something we consider. In a new dissertation from Umeå University in Sweden, Olympia Karampela shows that our ability for timing is something that can be trained and it seems to be connected with our cognitive capacity.
› Verified 3 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Fresenius Medical Care Of Marlborough get infections in their blood each year compared to the number of infections expected for the center based on the national average.
Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
Infection Rate in facility | .48 (As Expected) |
SIR: Upper Confidence Limit | 1.59 |
SIR: Lower Confidence Limit | .08 |
News Archive
Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that it has raised $33.9 million in a Series B funding round, led by new investor, New Enterprise Associates ("NEA"), one of the world's leading venture capital firms. Existing investor, Sofinnova Partners, also participated in the financing.
Mylan Inc. today announced the U.S. launch of its Methocarbamol Injection USP, 100 mg/mL, packaged in 1,000 mg/10 mL single-dose vials. This product is the generic version of Hikma Maple Ltd.'s Robaxin.
Eclipsys Corporation®, The Outcomes Company®, today announced that Singapore General Hospital, Singapore's oldest and largest acute tertiary hospital and national referral center, has been recognized as a winner of the Microsoft HUG 2010 Innovation Awards in the category of "Best Use of Clinical Records — Inpatient."
Good timing is vital in many situations of daily life, but is rarely something we consider. In a new dissertation from Umeå University in Sweden, Olympia Karampela shows that our ability for timing is something that can be trained and it seems to be connected with our cognitive capacity.
› Verified 3 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Fresenius Medical Care Of Marlborough's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
Patients in facility's Transfusion Summary | 50 |
Transfusion Rate in facility | 8.8 (As Expected) |
Transfusion Rate: Upper Confidence Limit | 67.9 |
Transfusion Rate: Lower Confidence Limit | 1.5 |
News Archive
Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that it has raised $33.9 million in a Series B funding round, led by new investor, New Enterprise Associates ("NEA"), one of the world's leading venture capital firms. Existing investor, Sofinnova Partners, also participated in the financing.
Mylan Inc. today announced the U.S. launch of its Methocarbamol Injection USP, 100 mg/mL, packaged in 1,000 mg/10 mL single-dose vials. This product is the generic version of Hikma Maple Ltd.'s Robaxin.
Eclipsys Corporation®, The Outcomes Company®, today announced that Singapore General Hospital, Singapore's oldest and largest acute tertiary hospital and national referral center, has been recognized as a winner of the Microsoft HUG 2010 Innovation Awards in the category of "Best Use of Clinical Records — Inpatient."
Good timing is vital in many situations of daily life, but is rarely something we consider. In a new dissertation from Umeå University in Sweden, Olympia Karampela shows that our ability for timing is something that can be trained and it seems to be connected with our cognitive capacity.
› Verified 3 days ago
The rate of mortality show you whether patients who were being treated regularly at Fresenius Medical Care Of Marlborough lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
Patients in facility's Survival Summary | 351 |
Mortality Rate in facility | 16.1 (As Expected) |
Mortality Rate: Upper Confidence Limit | 21.1 |
Mortality Rate: Lower Confidence Limit | 12.1 |
News Archive
Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that it has raised $33.9 million in a Series B funding round, led by new investor, New Enterprise Associates ("NEA"), one of the world's leading venture capital firms. Existing investor, Sofinnova Partners, also participated in the financing.
Mylan Inc. today announced the U.S. launch of its Methocarbamol Injection USP, 100 mg/mL, packaged in 1,000 mg/10 mL single-dose vials. This product is the generic version of Hikma Maple Ltd.'s Robaxin.
Eclipsys Corporation®, The Outcomes Company®, today announced that Singapore General Hospital, Singapore's oldest and largest acute tertiary hospital and national referral center, has been recognized as a winner of the Microsoft HUG 2010 Innovation Awards in the category of "Best Use of Clinical Records — Inpatient."
Good timing is vital in many situations of daily life, but is rarely something we consider. In a new dissertation from Umeå University in Sweden, Olympia Karampela shows that our ability for timing is something that can be trained and it seems to be connected with our cognitive capacity.
› Verified 3 days ago
Fresenius Medical Care Of Marlborough Location: 360 Cedar Hill Street, Marlborough, Massachusetts, 01752 Phone: (508) 460-9250 |
News Archive
Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that it has raised $33.9 million in a Series B funding round, led by new investor, New Enterprise Associates ("NEA"), one of the world's leading venture capital firms. Existing investor, Sofinnova Partners, also participated in the financing.
Mylan Inc. today announced the U.S. launch of its Methocarbamol Injection USP, 100 mg/mL, packaged in 1,000 mg/10 mL single-dose vials. This product is the generic version of Hikma Maple Ltd.'s Robaxin.
Eclipsys Corporation®, The Outcomes Company®, today announced that Singapore General Hospital, Singapore's oldest and largest acute tertiary hospital and national referral center, has been recognized as a winner of the Microsoft HUG 2010 Innovation Awards in the category of "Best Use of Clinical Records — Inpatient."
Good timing is vital in many situations of daily life, but is rarely something we consider. In a new dissertation from Umeå University in Sweden, Olympia Karampela shows that our ability for timing is something that can be trained and it seems to be connected with our cognitive capacity.
› Verified 3 days ago